In 2023, James E. Davis earned $2.88M in total compensation at Quest Diagnostics, including $1.18M salary and $1.36M bonus. Most recently acquired 13,390 shares in Feb 2024. Currently holds stock worth $32.04M. 3+ years at the helm of Quest Diagnostics.
Compensation History
Annual executive compensation data for James E. Davis, including salary, bonuses, and stock awards.
Year
2023
Total Compensation
$2.88M
Salary
$1.18M
Bonus
$1.36M
Other
$346.71K
Salary
$1.18MBoard Justification
The compensation philosophy is designed to align executive pay with performance, ensuring that a significant portion of compensation is at risk and tied to the company's financial and operational success.
Bonus
$1.36MBoard Justification
Annual cash incentive compensation based on performance against financial and non-financial goals for 2023, with a payout factor of 77.25% of target due to adjustments for profitability shortfalls.
Other Compensation
$346.71KBoard Justification
Other compensation includes matching contributions under the 401(k) Plan, matching credits under the Supplemental Deferred Compensation Plan, personal ground transportation, personal use of company aircraft, executive physical, relocation expenses, and tax and financial planning services.
Restricted Stock
Board Justification
No stock grants vested in 2023 as the performance shares are subject to a three-year performance period ending December 31, 2025.
Performance Metrics
Performance metrics for 2023 included adjusted diluted EPS, base business revenue, acquired revenue, and non-financial goals related to medical quality, customer experience, employee experience, and ESG initiatives.
James E. Davis
CEO of Quest Diagnostics
Sector of Economy
Healthcare
Born
July 30, 2024 - 1 years ago
CEO of Quest Diagnostics for
3 years 1 month (Nov 2022 - Present)
Previous Experience
Unknown
Other Quest Diagnostics CEOs
Holdings
Track James E. Davis's stock holdings and portfolio value over time.
Total Stock Sold
$28.04M
$28.04M
276,126 DGX shares
What if they kept their stock?
If James E. Davis didn't sell their stock, today they would have:
Extra DGX276,126 shares worth $50.40M.
This is 79.73% and $22.36M more than what they got when they sold the stock.
Insider Trading
James E. Davis's recent stock transactions, purchases, and sales filed with the SEC.
$1.67M
DGX at $125.02/share
Feb 23, 2024
Received
22,251 shares
DGX
Feb 14, 2024
Received
$2.25M
DGX at $147.86/share
Mar 6, 2023
Received
17,443 shares
DGX
Feb 23, 2023
Received
13,980 shares
DGX
Nov 1, 2022
Received
$2.58M
DGX at $130.09/share
Mar 7, 2022
Received
9,787 shares
DGX
Feb 24, 2022
Received
$1.91M
DGX at $115.42/share
Mar 9, 2021
Received
5,665 shares
DGX
Feb 17, 2021
Received
$308.25K
DGX at $87.75/share
Mar 16, 2020
Sale
Rivals
Compare James E. Davis with competitor CEOs and industry peers.
August J. Troendle
Founder and CEO of Medpace Holdings, Inc.
2023 Compensation
Stock
$0.00
Salary
$825.00K
Bonus
$814.42K
Other
$17.33K
Total Holdings
$513.58M
Stanley M. Bergman
CEO of Henry Schein
2023 Compensation
Stock
$0.00
Salary
$1.63M
Bonus
$643.65K
Other
$341.74K
Total Holdings
$49.43M
Adam H. Schechter
CEO of Labcorp Holdings
2023 Compensation
Stock
$750.00K
Salary
$1.20M
Bonus
$300.00K
Other
$150.00K
Total Holdings
$91.43M